Chairman increases holdings in Diamyd

The Chairman of Diamyd Medical, Anders Essen-Möller, has today bought 1,429,656 shares in Diamyd Medical and his holdings in Diamyd Medical amounts after the transaction to 479,292 series A-shares and 1,617,397 series B-shares, representing approximately 21% of the capital and about 45% of the votes.

For further information, please contact:
Peter Zerhouni, President and CEO Diamyd Medical AB
Phone: +46 8 661 00 26. E-mail: press@diamyd.com

About Diamyd Medical
Diamyd Medical is a Swedish diabetes company. The company was formerly called Diamyd Therapeutics and was spun off from Mertiva AB (formerly Diamyd Medical) in April 2013. The company’s primary development project consists of the GAD-based diabetes vaccine Diamyd®for the treatment and prevention of autoimmune diabetes. Two researcher-initiated Phase II studies with Diamyd®are currently ongoing. One study evaluates whether the diabetes vaccine can prevent type 1 diabetes in children who are at high risk of developing the disease and one study evaluates whether Diamyd®in combination with relatively high doses of vitamin D and ibuprofen can preserve the body's own ability to regulate the blood sugar level in children and adolescents newly diagnosed with type 1 diabetes.

Diamyd Medical also has holdings in the gene therapy company Periphagen Holdings, Inc. (US).

Diamyd Medical’s shares will be traded on NASDAQ OMX First North as of May 20, 2013 under the ticker DMYD B. Remium Nordic AB is the company’s certified adviser. Further information is available on the company’s website: www.diamyd.com.

Diamyd Medical AB (publ)
Kungsgatan 29, SE-111 56 Stockholm, Sweden. Phone: +46 8 661 00 26, Fax: +46 8 661 63 68
E-mail: info@diamyd.com. Reg. no.: 556242-3797.

Tags:

About Us

Diamyd Medical is a Swedish diabetes company dedicated to finding a cure for autoimmune diabetes through pharmaceutical development and investments in stem cell- and medical technology.

Subscribe

Documents & Links